Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Glycoprotein Hormone & Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for hCG Alpha/CGA drug discovery and diagnostic development. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human CGA (Glycoprotein Hormones Alpha Chain) Protein HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin Controlled (<1 EU/ug), Sequence Verified. |
View CGA Products |
| Gene Delivery | CGA Lentiviral Particles / Promise-ORF Full-length human CGA ORF for stable cell line generation and expression assays. |
View CGA Products |
| Benchmark Ab | Anti-CGA Recombinant Antibody High-affinity positive control clone for ELISA, Western Blot, and immunohistochemistry. |
View CGA Products |
| Validator | CGA siRNA Set Target-specific knockdown pool for functional validation and specificity screening. |
View CGA Products |
| Related Target A | CGB (Chorionic Gonadotropin Subunit Beta) The beta subunit conferring hormone specificity; essential for heterodimer reconstitution assays. |
View CGB Products |
| Related Target B | TSHB (Thyroid Stimulating Hormone Subunit Beta) Crucial for counter-screening to eliminate cross-reactivity with thyroid-stimulating pathways. |
View TSHB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-reactivity with other glycoprotein hormones (LH, FSH, TSH) | High-purity human CGA, CGB, and TSHB recombinant panels strictly verified by Mass Spectrometry for structural integrity. |
| Loss of native post-translational modifications (glycosylation) | Exclusively expressed in HEK293 mammalian systems to preserve complex N-linked glycans essential for native epitope presentation. |
| Assay background and false positives | Endotoxin-controlled production (<1.0 EU/ug) and sequence-verified recombinant benchmark antibodies ensure high signal-to-noise ratios. |
| Lack of stable target expression in screening lines | High-titer, integration-ready Lentiviral Particles designed for robust, long-term CGA expression. |
Live hCG Alpha/CGA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic and diagnostic targeting of CGA (Glycoprotein Hormones Alpha Chain) is undergoing a significant shift. While historically centered on reproductive medicine and fertility (as part of heterodimeric hCG, LH, and FSH), CGA is increasingly recognized as a vital biomarker and therapeutic target in oncology. Free alpha subunit (CGA) hypersecretion is a documented hallmark of specific neuroendocrine tumors (NETs), pituitary adenomas, and aggressive gynecological cancers.
The race for CGA-related therapeutics is intensifying, with major players shifting focus from traditional hormone replacement therapies to highly selective monoclonal antibodies and antibody-drug conjugates (ADCs) capable of distinguishing free CGA from physiological heterodimers. As next-generation diagnostics and targeted therapies enter preclinical validation, the next wave of R&D is targeting glycoform-specific epitopes and tumor-secreted free subunits to minimize systemic endocrine toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Diagnostic Monoclonal Abs | Roche, Abbott, Siemens Healthineers | Neuroendocrine Tumors, Pituitary Adenomas, Pregnancy Monitoring | High-purity recombinant CGA with native glycosylation for calibrator and assay development. |
| Therapeutic Antibodies | Academic Institutes, Biopharma Consortia | Oncology (CGA-secreting tumors), Endocrine disorders | Cross-reactivity panels (CGA vs. intact hCG/LH/FSH/TSH) to confirm subunit-specific binding. |
| RNA Interference (siRNA) | Preclinical Biotech Developers | Hormone-dependent cancers, hypersecretion syndromes | Sequence-verified CGA siRNA sets for robust in vitro target knockdown and validation. |